As GLP-1 weight-loss drugs have boosted several healthcare stocks, Jennison Associates Head of Global Equity Mark Baribeau joins Market Domination Overtime to discuss whether these companies can keep up the momentum.) as companies seeing major revenue growth and likely to split the market. He sees weight-loss and type 2 diabetes drugs as a"paradigm shift" that present huge opportunities for both companies.
However, he notes that while consumer demand for these drugs is skyrocketing, Novo Nordisk and Eli Lilly"don't have the manufacturing capacity to keep up with demand. So the gating factor here is really supply. It's not demand."But this time in health care and we're talking about uh being overweight and also diabetes, we've seen Novo Nordisk, we've seen Eli Lilly surge in various fits and starts, but this seems like we're still in the opening innings here.
Devin Nunes, CEO of Trump Media & Technology Group , in a letter to Nasdaq CEO Adena Friedman said that he has requested Congress to urge the Financial Industry Regulatory Authority to issue electronic blue sheets for TMTG's trading data from April 29 through May 3 and some other dates from May and June. Electronic blue sheet data contains both trading and account holder information, which provide regulatory agencies with the ability to analyze a firm's trading activity.
These three Canadian stocks are an excellent addition to your portfolios in this volatile environment. The post 3 of the Best Stocks to Buy Right Now in Canada appeared first on The Motley Fool Canada.Investing in blue-chip TSX dividend stocks such as RBC and CNR can help you earn passive income for life. The post Want Decades of Passive Income? 3 Stocks to Buy Now and Hold Forever appeared first on The Motley Fool Canada.
Finance Finance Latest News, Finance Finance Headlines
Similar News:You can also read news stories similar to this one that we have collected from other news sources.
Source: YahooFinanceCA - 🏆 47. / 63 Read more »